From protocol amendments to participant recruitment and retention, the impact of COVID-19 could be enormous. What can you do to minimize the disruption to your ongoing, or upcoming, clinical trial? Our panel of experts from NYU Langone Medical Center and WCG discuss ways to reduce the impact of this pandemic on your studies to keep them on track.
Other content in this Stream
We Should Not Be Surprised: COVID-19 Disparities Lay Bare What’s Been There All Along
In this episode, former Assistant FDA Commissioner Jonca Bull, MD, discusses racial disparities in healthcare, how COVID-19 has made them impossible to ignore, and how this highlights the need for div
COVID-19 Insights from Former FDA Commissioner, Scott Gottlieb, MD
The coronavirus has spread beyond the point of containment, and there’s a looming shortage of personal protective equipment. Hear insights from former FDA Commissioner, Scott Gottlieb, MD.
COVID-19 Preparedness for Health Care Institutions with Dr. Paul Biddinger of Massachusetts General Hospital
Infectious Disease Challenge Studies: Ethical Issues in Causing Disease for Medical Knowledge
Part 6: Going Remote During COVID-19: Considerations When Moving Studies Out of the Clinic Setting
Part 4: Planning for Recovery: How Research Sponsors and Research Sites are Thinking Ahead to Restart Research
Part 3: Evaluating Study Status and Leveraging Data Monitoring Committees to Make Study Decisions